1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Dunsire Takes XTuit Helm As First Targets Approach The Clinic

 
• By Jessica Merrill

The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.

Privately-held XTuit Pharmaceuticals Inc. has tapped experienced oncology leader Deborah Dunsire as president and CEO as the company’s lead drugs mature towards the clinic. The Waltham, Massachusetts-based firm, focused on developing novel drugs targeting the disease-promoting microenvironment in fibrotic diseases and cancer, expects to bring its first drug into the clinic in 2018.

Dunsire has a long track record building drug companies. She is perhaps most recognized for running the cancer company Millennium...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Anticancer

More from Therapy Areas

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.